Enovis Q3 EPS beats estimates; raises FY profit outlook
Overview
U.S. medical technology firm's Q3 sales slightly beat analyst expectations, rising 2% yr/yr
Adjusted EPS for Q3 beat analyst expectations
Company raised full-year 2026 adjusted EBITDA and EPS guidance
Board approved new $200 mln share repurchase authorization
Outlook
Enovis narrows 2026 revenue guidance to $2.32-2.35 bln, from $2.31-2.37 bln
Company raises 2026 adj EBITDA outlook to $428-438 mln, from $425-435 mln
Enovis lifts 2026 adj EPS guidance to $3.58-3.79, from $3.52-3.73
Result Drivers
RECONSTRUCTIVE SEGMENT - Co said 6% sales growth in its Reconstructive (Recon) business was a key driver for the quarter
NEW PRODUCT MOMENTUM - Co cited encouraging momentum in new product introductions as supporting quarterly results
COST INFLATION AND VOLATILITY - Co noted ongoing market volatility and cost inflation as challenges during the quarter
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Sales | Slight Beat* | $558.73 mln | $557.01 mln (13 Analysts) |
Q3 Adjusted EPS | Beat | $0.88 | $0.77 (13 Analysts) |
Q3 Gross Margin | 60.80% |
*Applies to a deviation of less than 1%; not applicable for per-share numbers.
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Enovis Corporation is $36.00, about 47.4% above its November 4 closing price of $24.42
The stock recently traded at 7 times the next 12-month earnings vs. a P/E of 8 three months ago
Reuters Recommended Reads
Nov 4 - Zimmer Biomet Q3 sales beat estimates, raises FY outlook
Nov 4 - Insulet Q3 revenue beats estimates on strong Omnipod sales
Nov 4 - Smith+Nephew cuts outlook after failed orthopaedics deal talks with J&J
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)